GlassScriptPhysician profile
Taras Yurchenko
NPI 1912559782
$7,706.83
in general payments reported to CMS, 2019-2025
26 companies · $2,709 in 2025
The $2,709 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $681 · 2022: $1,120 · 2023: $1,382 · 2024: $1,814 · 2025: $2,709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,682 · Education: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,681.95 |
| Education | $223.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,549.25 | 2021-2025 | |
| Janssen Biotech, INC. | $1,243.72 | 2021-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $1,044.11 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $689.70 | 2022-2025 | |
| Amgen INC. | $473.33 | 2021-2025 | Evenity, Krystexxa, Prolia |
| Mallinckrodt Hospital Products INC. | $415.34 | 2024-2025 | Acthar |
| Glaxosmithkline, LLC. | $407.32 | 2021-2025 | Benlysta |
| Radius Health, INC. | $307.04 | 2021-2025 | Tymlos |
| Lilly USA, LLC | $298.47 | 2021-2025 | Taltz, Omvoh, Zepbound |
| Pfizer INC. | $179.39 | 2022-2025 | |
| Genentech USA, INC. | $154.02 | 2022-2025 | Actemra, Ocrevus Zunovo |
| E.R. Squibb & Sons, L.L.C. | $150.89 | 2021-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $136.72 | 2021-2023 | Saphnelo |
| Alexion Pharmaceuticals, INC. | $118.77 | 2023-2025 | Strensiq |
| Fresenius Kabi USA, LLC | $106.16 | 2023-2025 | Idacio |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $69.14 | 2022-2025 | Nexplanon, Hadlima, Renflexis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.41 | 2022-2024 | Spevigo, Cyltezo |
| Aurinia Pharma U.S., INC. | $56.58 | 2025 | Lupkynis |
| Horizon Therapeutics Plc | $51.27 | 2021-2023 | Krystexxa |
| Eisai INC. | $37.95 | 2023 | |
| Medtronic, INC. | $30.96 | 2024 | Intellis Adaptivestim |
| Pacira Therapeutics, INC. | $30.58 | 2021 | |
| Lundbeck LLC | $27.65 | 2022 | |
| Genzyme Corporation | $27.37 | 2023 | |
| Ani Pharmaceuticals, INC. | $18.75 | 2025 | Purified Cortrophin Gel |
| Fidia Pharma USA INC. | $15.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taras Yurchenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.